Trials / Completed
CompletedNCT00223925
Maribavir for Prevention of CMV After Stem Cell Transplants
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maribavir | |
| DRUG | Placebo |
Timeline
- Start date
- 2004-10-28
- Primary completion
- 2006-04-05
- Completion
- 2006-04-05
- First posted
- 2005-09-22
- Last updated
- 2021-05-13
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00223925. Inclusion in this directory is not an endorsement.